FGF19 and obesity due to melanocortin 4 receptor deficiency: The discovery of endocrine fibroblast growth factors (FGF), including FGF-21 and FGF-19, has uncovered new mechanisms that regulate metabolism and lipid homeostasis, and has provided potential therapeutic targets for type 2 diabetes, obesity, and hepatic steatosis [23].